Identification of a glutathione peroxidase inhibitor that reverses resistance to anticancer drugs in human B-cell lymphoma cell lines

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6712-5. doi: 10.1016/j.bmcl.2012.08.091. Epub 2012 Sep 5.

Abstract

Cancer cells isolated from two patients with malignant non-Hodgkin B-cell lymphomas that became resistant to chemotherapy during clinical treatment were made ≥fourfold resistant in culture to anticancer drugs, that is cisplatin, etoposide, methotrexate and bortezomib. Because most resistant lines showed significantly increased expression of the anti-oxidative enzyme glutathione peroxidase 1 (GPx1), GPx1 was investigated as a target for inhibitor development. Virtual screening of a library of diverse structures by docking them to the active site of the X-ray crystal structure of bovine GPx1 uncovered compounds that might block the enzyme. An enzyme assay confirmed an acylhydrazone heterocycle (3) with GPx inhibitory activity. Combinations of 3 with the anticancer drugs listed above led to reversal of resistance in the lymphoma cell lines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Catalytic Domain
  • Cattle
  • Cell Line, Tumor
  • Crystallography, X-Ray
  • Drug Resistance, Neoplasm / drug effects*
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology*
  • Glutathione Peroxidase / antagonists & inhibitors*
  • Humans
  • Hydrazones / chemical synthesis*
  • Hydrazones / chemistry
  • Hydrazones / pharmacology*
  • Inhibitory Concentration 50
  • Lymphoma, B-Cell
  • Molecular Structure

Substances

  • Enzyme Inhibitors
  • Hydrazones
  • Glutathione Peroxidase